Open Access. Powered by Scholars. Published by Universities.®
Virginia Commonwealth University
IMMUNODEFICIENCY-VIRUS INFECTION; PROPHYLAXIS; SULFAMETHOXAZOLE; METAANALYSIS; ENCEPHALITIS; INTOLERANT; EFFICACY; 566C80; AIDS
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Atovaquone Compared With Dapsone For The Prevention Of Pneumocystis Carinii Pneumonia In Patients With Hiv Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, Or Both, Wafaa M. El-Sadr , M.D., M.P.H., Robert L. Murphy , M.D., Teresa Mccabe Yurik , M.S., Roberta Luskin-Hawk , M.D., Tony W. Cheung , M.D., Henry H. Balfour , Jr., M.D., Robert Eng , M.D., Thomas M. Hooton , M.D., Thomas M. Kerkering , M.D., Malte Schutz , M.D., Charles Van Der Horst , M.D., Richard Hafner , M.D.
Atovaquone Compared With Dapsone For The Prevention Of Pneumocystis Carinii Pneumonia In Patients With Hiv Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, Or Both, Wafaa M. El-Sadr , M.D., M.P.H., Robert L. Murphy , M.D., Teresa Mccabe Yurik , M.S., Roberta Luskin-Hawk , M.D., Tony W. Cheung , M.D., Henry H. Balfour , Jr., M.D., Robert Eng , M.D., Thomas M. Hooton , M.D., Thomas M. Kerkering , M.D., Malte Schutz , M.D., Charles Van Der Horst , M.D., Richard Hafner , M.D.
Internal Medicine Publications
BACKGROUND
Although trimethoprim–sulfamethoxazole is the drug of choice for the prevention of Pneumocystis carinii pneumonia, many patients cannot tolerate it and must switch to an alternative agent.
METHODS
We conducted a multicenter, open-label, randomized trial comparing daily atovaquone (1500-mg suspension) with daily dapsone (100 mg) for the prevention of P. carinii pneumonia among patients infected with the human immunodeficiency virus who could not tolerate trimethoprim–sulfamethoxazole. The median follow-up period was 27 months.
RESULTS
Of 1057 patients enrolled, 298 had a history of P. carinii pneumonia.P. cariniipneumonia developed in 122 of 536 patients assigned to atovaquone (15.7 cases per …